The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
about
Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolaseImpact of soluble epoxide hydrolase and epoxyeicosanoids on human healthSoluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociceptionCrystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factorArachidonic acid cytochrome P450 epoxygenase pathwayArachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevanceCytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolismThe role of long chain fatty acids and their epoxide metabolites in nociceptive signalingSoluble epoxide hydrolase: A potential target for metabolic diseasesEstrogen, aging and the cardiovascular systemSoluble epoxide hydrolase inhibitors and heart failureOpposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosisEpoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor responseSoluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophyRed blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP)Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistanceAlteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolaseSoluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single AgentThe 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic painPharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in ratsDevelopment of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted librariesSoluble epoxide hydrolase in atherosclerosisAnti-Ulcer Efficacy of Soluble Epoxide Hydrolase Inhibitor TPPU on Diclofenac-Induced Intestinal UlcersRedox regulation of soluble epoxide hydrolase by 15-deoxy-delta-prostaglandin J2 controls coronary hypoxic vasodilationPharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsAberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis modelInhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal diseaseInhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse modelThe anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injuryEpoxyeicosatrienoic acids mediate insulin-mediated augmentation in skeletal muscle perfusion and blood volumePharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in miceBiological evaluation of a novel sorafenib analogue, t-CUPM
P2860
Q24310374-89D66646-4496-4F12-8C18-4F8377738B32Q24618018-DDC4FA28-2547-4D3D-BF24-56DA8F28F9A6Q24628660-5F58BB13-1DA6-472F-9CBD-8411298C08DDQ24629214-DA232175-C6C0-41F8-8E94-4CB24B8910B7Q24653023-0F8C0BD0-69D3-41AE-8C5A-DCAD63270677Q27024958-150188B7-E6A6-4F59-95AD-24600C5F410DQ28245279-E9C4DC84-5F27-4094-9763-1D2669B05F68Q28248377-5E543E6A-2BCE-4E01-9F4E-971F0F45C182Q28270454-78A070C9-986F-4D6F-9BEE-0E67E268EEA2Q28383144-45F064B0-8493-4FFB-B2D3-395201F4DA2DQ28383423-DB67CCD3-1B80-429B-B27D-63FA038AAF5EQ28383719-F50E9C59-4693-47C7-8A4B-D71943AC903FQ28386966-1A83241C-1D46-440C-9C27-D44B380BDE32Q28387081-CB0AB291-135E-4697-913E-B7111BD8D495Q28388012-2996518E-B1B5-4FB3-A530-BAFB7811D03AQ28388993-C1D2480E-E921-417A-B68D-990957D495F7Q28390217-46CBA68D-53F3-4FB7-BE55-C32717A3239EQ28391163-A287853F-C726-4AE1-BDDE-A91A276BE125Q28392416-3D105E36-2FE9-42FB-A620-C3C1CA775ECAQ28392609-76B6D453-3183-491B-9608-4537FD8DAA78Q28393751-6A1FE166-956D-4E50-AE79-3EC2BCB18E1AQ28395004-DBFEBBFB-E457-4834-9B3E-7A9E86B8D6ECQ28395478-09DC8B21-6259-49E6-8C62-8C3E17F10B1BQ28395654-716D47EF-40CF-49DD-99C6-2595B18B3375Q28396888-5250A796-FEB1-49B1-95FF-8138E34CF89BQ28397805-B46A7C65-0F85-480D-96EF-803AC96E8270Q33652488-A34E7C42-FDA1-40BC-8AF4-B3CC8FB0399DQ33665713-6ED52B79-96C1-4711-8D33-DCD8410B3C04Q33714587-B04BAE9E-DBD5-4EA1-BF9E-BB55E8B966BBQ33738489-69102997-E694-443F-B46F-87D0F91B435BQ33800226-CFE36483-A6A5-4C46-91E1-70A1C24BF260Q33814824-A57D795C-6709-4AB3-8729-99B0A92706CDQ33882374-E862B996-F688-4232-9B13-22EAA83FFACDQ34035269-424CF3D9-6AA7-4729-A102-57E18251DA06Q34588685-AC1BBF9C-CEE5-464F-9706-57853BF82D10Q34726749-790471FD-0EF2-425C-8A21-09EC5F6BE8F4Q35115765-4937D00E-88B2-40B8-9CB5-D565E3285220Q35116083-1CFE0367-F5AA-4073-97FA-D3846E20C857Q35427989-EA6AB8AE-525E-47CB-95FA-E2EEF4F7CA63Q35448698-631BD6E7-811B-4C10-8BC7-9575D6A01718
P2860
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
@en
type
label
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
@en
prefLabel
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
@en
P2093
P1476
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
@en
P2093
Bruce D Hammock
Chin-Min Ho
Hsing-Ju Tsai
Nipavan Chiamvimonvat
P304
P356
10.1097/FJC.0B013E3181506445
P407
P577
2007-09-01T00:00:00Z